Cite
HARVARD Citation
Strober, B. et al. (2022). Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. Journal of dermatological treatment. pp. 2991-2996. [Online].